140 related articles for article (PubMed ID: 37830752)
1. Measurement of Trogocytosis: Quantitative Analyses Validated with Rigorous Controls.
Taylor RP; Lindorfer MA
Curr Protoc; 2023 Oct; 3(10):e897. PubMed ID: 37830752
[TBL] [Abstract][Full Text] [Related]
2. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
Beum PV; Peek EM; Lindorfer MA; Beurskens FJ; Engelberts PJ; Parren PW; van de Winkel JG; Taylor RP
J Immunol; 2011 Sep; 187(6):3438-47. PubMed ID: 21841127
[TBL] [Abstract][Full Text] [Related]
3. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
Beum PV; Mack DA; Pawluczkowycz AW; Lindorfer MA; Taylor RP
J Immunol; 2008 Dec; 181(11):8120-32. PubMed ID: 19018005
[TBL] [Abstract][Full Text] [Related]
4. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
[TBL] [Abstract][Full Text] [Related]
5. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
[TBL] [Abstract][Full Text] [Related]
6. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes.
Beum PV; Kennedy AD; Williams ME; Lindorfer MA; Taylor RP
J Immunol; 2006 Feb; 176(4):2600-9. PubMed ID: 16456022
[TBL] [Abstract][Full Text] [Related]
7. Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies.
Valgardsdottir R; Cattaneo I; Klein C; Introna M; Figliuzzi M; Golay J
Blood; 2017 May; 129(19):2636-2644. PubMed ID: 28288980
[TBL] [Abstract][Full Text] [Related]
8. Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice.
Boross P; Jansen JH; Pastula A; van der Poel CE; Leusen JH
Immunol Lett; 2012 Mar; 143(1):44-52. PubMed ID: 22285696
[TBL] [Abstract][Full Text] [Related]
9. Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments.
Taylor RP; Lindorfer MA
Blood; 2015 Jan; 125(5):762-6. PubMed ID: 25498911
[TBL] [Abstract][Full Text] [Related]
10. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
[TBL] [Abstract][Full Text] [Related]
11. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.
Bologna L; Gotti E; Da Roit F; Intermesoli T; Rambaldi A; Introna M; Golay J
J Immunol; 2013 Jan; 190(1):231-9. PubMed ID: 23225880
[TBL] [Abstract][Full Text] [Related]
12. FcγR-Mediated Trogocytosis 2.0: Revisiting History Gives Rise to a Unifying Hypothesis.
Lindorfer MA; Taylor RP
Antibodies (Basel); 2022 Jul; 11(3):. PubMed ID: 35892705
[TBL] [Abstract][Full Text] [Related]
13. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.
Baig NA; Taylor RP; Lindorfer MA; Church AK; LaPlant BR; Pettinger AM; Shanafelt TD; Nowakowski GS; Zent CS
J Immunol; 2014 Feb; 192(4):1620-9. PubMed ID: 24431228
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of macrophage trogocytosis of rituximab-coated B cells.
Pham T; Mero P; Booth JW
PLoS One; 2011 Jan; 6(1):e14498. PubMed ID: 21264210
[TBL] [Abstract][Full Text] [Related]
15. Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.
Skarzynski M; Niemann CU; Lee YS; Martyr S; Maric I; Salem D; Stetler-Stevenson M; Marti GE; Calvo KR; Yuan C; Valdez J; Soto S; Farooqui MZ; Herman SE; Wiestner A
Clin Cancer Res; 2016 Jan; 22(1):86-95. PubMed ID: 26283682
[TBL] [Abstract][Full Text] [Related]
16. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
Beum PV; Lindorfer MA; Taylor RP
J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
[TBL] [Abstract][Full Text] [Related]
17. Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics.
Felberg A; Urban A; Borowska A; Stasiłojć G; Taszner M; Hellmann A; Blom AM; Okrój M
Cancer Immunol Immunother; 2019 Apr; 68(4):587-598. PubMed ID: 30725204
[TBL] [Abstract][Full Text] [Related]
18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
19. Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies.
Taylor RP; Lindorfer MA
Mol Pharmacol; 2014 Nov; 86(5):485-91. PubMed ID: 24944188
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
Rossi EA; Chang CH; Goldenberg DM
PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]